Ignite Creation Date:
2024-05-06 @ 5:58 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05493215
Status:
RECRUITING
Last Update Posted:
2024-04-01
First Post:
2022-08-05
Brief Title:
Imatinib TDM in GIST
Sponsor:
Reema A Patel
Organization:
University of Kentucky
Study Overview
Official Title:
A Phase 2 Study of Imatinib Therapeutic Drug Monitoring in Gastrointestinal Stromal Tumor
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors GIST however side effects can significantly hinder quality of life for our patients This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels Free drug levels and pharmokinetics of imatinib will also be monitored
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None